David Lebowitz
Stock Analyst at Citigroup
(3.94)
# 622
Out of 5,008 analysts
119
Total ratings
59.77%
Success rate
8.42%
Average return
Main Sectors:
Stocks Rated by David Lebowitz
Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
---|---|---|---|---|---|---|---|
IONS Ionis Pharmaceuticals | Maintains: Buy | $69 → $84 | $69.03 | +21.69% | 14 | Sep 3, 2025 | |
CYTK Cytokinetics | Maintains: Buy | $77 → $84 | $60.64 | +38.52% | 4 | Sep 2, 2025 | |
CLDX Celldex Therapeutics | Maintains: Buy | $56 → $48 | $26.37 | +82.03% | 2 | Aug 20, 2025 | |
SDGR Schrödinger | Downgrades: Neutral | $35 → $20 | $21.29 | -6.06% | 10 | Aug 15, 2025 | |
ASND Ascendis Pharma | Maintains: Buy | $243 → $290 | $210.83 | +37.55% | 14 | Aug 8, 2025 | |
INCY Incyte | Maintains: Buy | $88 → $103 | $87.23 | +18.08% | 6 | Jul 30, 2025 | |
VKTX Viking Therapeutics | Maintains: Neutral | $31 → $38 | $32.28 | +17.72% | 2 | Jul 24, 2025 | |
COGT Cogent Biosciences | Maintains: Buy | $15 → $22 | $15.90 | +38.36% | 4 | Jul 18, 2025 | |
BBIO BridgeBio Pharma | Maintains: Buy | $58 → $67 | $54.61 | +22.69% | 5 | Jul 11, 2025 | |
EXEL Exelixis | Maintains: Buy | $45 → $56 | $39.99 | +40.04% | 3 | May 15, 2025 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $14 → $10 | $20.54 | -51.31% | 8 | May 9, 2025 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $4 → $1.5 | $1.48 | +1.35% | 6 | Mar 4, 2025 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sell | $32 → $45 | $64.81 | -30.57% | 4 | Feb 12, 2025 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $65 → $68 | $72.45 | -6.14% | 4 | Nov 13, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $382 | $442.31 | -13.64% | 1 | Mar 6, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $103 → $96 | $55.61 | +72.63% | 3 | Jun 30, 2023 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $18 → $12 | $6.28 | +91.08% | 2 | Jul 15, 2022 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $170 → $164 | $452.00 | -63.72% | 7 | Jul 15, 2022 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $36 → $39 | $19.76 | +97.37% | 6 | Jun 7, 2022 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $20 → $21 | $16.41 | +27.97% | 11 | Oct 12, 2021 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $435 → $405 | $6.16 | +6,474.68% | 1 | Oct 12, 2021 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $13 → $14 | $1.48 | +845.95% | 2 | Oct 12, 2021 |
Ionis Pharmaceuticals
Sep 3, 2025
Maintains: Buy
Price Target: $69 → $84
Current: $69.03
Upside: +21.69%
Cytokinetics
Sep 2, 2025
Maintains: Buy
Price Target: $77 → $84
Current: $60.64
Upside: +38.52%
Celldex Therapeutics
Aug 20, 2025
Maintains: Buy
Price Target: $56 → $48
Current: $26.37
Upside: +82.03%
Schrödinger
Aug 15, 2025
Downgrades: Neutral
Price Target: $35 → $20
Current: $21.29
Upside: -6.06%
Ascendis Pharma
Aug 8, 2025
Maintains: Buy
Price Target: $243 → $290
Current: $210.83
Upside: +37.55%
Incyte
Jul 30, 2025
Maintains: Buy
Price Target: $88 → $103
Current: $87.23
Upside: +18.08%
Viking Therapeutics
Jul 24, 2025
Maintains: Neutral
Price Target: $31 → $38
Current: $32.28
Upside: +17.72%
Cogent Biosciences
Jul 18, 2025
Maintains: Buy
Price Target: $15 → $22
Current: $15.90
Upside: +38.36%
BridgeBio Pharma
Jul 11, 2025
Maintains: Buy
Price Target: $58 → $67
Current: $54.61
Upside: +22.69%
Exelixis
May 15, 2025
Maintains: Buy
Price Target: $45 → $56
Current: $39.99
Upside: +40.04%
May 9, 2025
Maintains: Neutral
Price Target: $14 → $10
Current: $20.54
Upside: -51.31%
Mar 4, 2025
Maintains: Neutral
Price Target: $4 → $1.5
Current: $1.48
Upside: +1.35%
Feb 12, 2025
Maintains: Sell
Price Target: $32 → $45
Current: $64.81
Upside: -30.57%
Nov 13, 2024
Maintains: Buy
Price Target: $65 → $68
Current: $72.45
Upside: -6.14%
Mar 6, 2024
Initiates: Buy
Price Target: $382
Current: $442.31
Upside: -13.64%
Jun 30, 2023
Maintains: Neutral
Price Target: $103 → $96
Current: $55.61
Upside: +72.63%
Jul 15, 2022
Maintains: Equal-Weight
Price Target: $18 → $12
Current: $6.28
Upside: +91.08%
Jul 15, 2022
Maintains: Equal-Weight
Price Target: $170 → $164
Current: $452.00
Upside: -63.72%
Jun 7, 2022
Maintains: Overweight
Price Target: $36 → $39
Current: $19.76
Upside: +97.37%
Oct 12, 2021
Maintains: Equal-Weight
Price Target: $20 → $21
Current: $16.41
Upside: +27.97%
Oct 12, 2021
Maintains: Overweight
Price Target: $435 → $405
Current: $6.16
Upside: +6,474.68%
Oct 12, 2021
Maintains: Equal-Weight
Price Target: $13 → $14
Current: $1.48
Upside: +845.95%